Fha Deficient Bordetella pertussis Isolates in Iran with 50 Years Whole Cell Pertussis Vaccination

Background: Bordetella pertussis, a highly contagious respiratory. Notably, the resurgence of pertussis has recently been associated with the lacking production of vaccine virulence factors. This study aimed to screen pertactin (Prn) and filamentous hemagglutinin (Fha) production in Iran with 50 years' whole cell vaccine (WCV) immunization program. Methods: Overall, 130 B. pertussis isolates collected from Pertussis Reference Laboratory of Iran during 2005-2018. Real-time PCR was performed by targeting IS481, ptxP, IS1001 and IS1002 for species confirmation of B. pertussis. Western-blot was used to evaluate the expression of virulence factors (pertactin and filamentous hemagglutinin). Results: All tested B. pertussis isolates expressed Prn and all except two isolates expressed Fha. We have sequenced genomes of these strains and identified differences compared with genome reference B. pertussis Tohama I. Conclusion: Many countries reporting Prn and Fha-deficiency due to acellular vaccine (ACV) pressure. Our results demonstrate in a country with WCV history, Fha-deficient isolates may rise independently. However, Prn-deficient isolates are more under the ACV pressure in B. pertussis isolates. Continues surveillance will provide a better understanding of the effect of WCV on the evolution of the pathogen deficiency.

Download Full-text

Long-term cellular memory immunity against Bordetella pertussis and other components of the DTP-IPV-Hib vaccine in Dutch children: comparison of a whole cell vaccine (WCV) with an acellular vaccine (ACV)

http://isrctn.org/> ◽

10.1186/isrctn65428640 ◽

2012 ◽

Cited By ~ 1

Author(s):

Lotte Hendrikx

Keyword(s):

Bordetella Pertussis ◽

Cell Vaccine ◽

Cellular Memory ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Dutch Children ◽

Acellular Vaccine

Download Full-text

Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine

Scientific Reports ◽

10.1038/srep38240 ◽

2016 ◽

Vol 6 (1) ◽

Cited By ~ 23

Author(s):

René H. M. Raeven ◽

Jolanda Brummelman ◽

Jeroen L. A. Pennings ◽

Larissa van der Maas ◽

Wichard Tilstra ◽

...

Keyword(s):

Outer Membrane ◽

Bordetella Pertussis ◽

Inflammatory Responses ◽

Membrane Vesicle ◽

Cell Vaccine ◽

Outer Membrane Vesicle ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Equal Efficacy

Download Full-text

Primary Immunization of Infants With an Acellular Pertussis Vaccine in a Double-Blind Randomized Clinical Trial

PEDIATRICS ◽

10.1542/peds.82.3.293 ◽

1988 ◽

Vol 82 (3) ◽

pp. 293-299

Author(s):

Margareta Blennow ◽

Marta Granström ◽

Eva Jäätmaa ◽

Patrick Olin

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Pertussis Vaccine ◽

Acellular Pertussis Vaccine ◽

Cell Vaccine ◽

Primary Immunization ◽

Double Blind ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Acellular Vaccine

The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization in 319 6-month-old infants in a double-blind randomized clinical trial. The acellular vaccine produced few and mild systemic and local reactions. Fever (≥38°C) occurred in 6% to 8% of acellular vaccinees as opposed to 25% to 37% of whole-cell vaccinees. Redness (≥1 cm) appeared in 2% to 13% of the acellular vaccine and 24% to 32% of the whole-cell vaccine recipients. Antibody response to pertussis toxin measured in a neutralization test was obtained in 97% to 100% of the infants receiving either two or three doses of the acellular vaccine as compared to 59% after three doses of whole-cell vaccine.

Download Full-text

Polymorphism of Bordetella pertussis Isolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell Vaccine Has Been Used for More than 30 Years

Journal of Clinical Microbiology ◽

10.1128/jcm.39.12.4396-4403.2001 ◽

2001 ◽

Vol 39 (12) ◽

pp. 4396-4403 ◽

Cited By ~ 104

Author(s):

C. Weber ◽

C. Boursaux-Eude ◽

G. Coralie ◽

V. Caro ◽

N. Guiso

Keyword(s):

Bordetella Pertussis ◽

Cell Vaccine ◽

Whole Cell ◽

Whole Cell Vaccine

Download Full-text

Antibody Responses to Bordetella pertussis Fim2 or Fim3 following Immunization with a Whole-Cell, Two-Component, or Five-Component Acellular Pertussis Vaccine and following Pertussis Disease in Children in Sweden in 1997 and 2007

Clinical and Vaccine Immunology ◽

10.1128/cvi.00641-13 ◽

2013 ◽

Vol 21 (2) ◽

pp. 165-173 ◽

Cited By ~ 9

Author(s):

Hans Hallander ◽

Abdolreza Advani ◽

Frances Alexander ◽

Lennart Gustafsson ◽

Margaretha Ljungman ◽

...

Keyword(s):

Pertussis Vaccine ◽

Bordetella Pertussis ◽

Geometric Mean ◽

Acellular Pertussis Vaccine ◽

Antibody Responses ◽

Cell Vaccine ◽

Whole Cell ◽

Content Type ◽

Two Component ◽

Whole Cell Vaccine

ABSTRACTBordetella pertussisfimbriae (Fim2 and Fim3) are components of a five-component acellular pertussis vaccine (diphtheria–tetanus–acellular pertussis vaccine [DTaP5]), and antibody responses to fimbriae have been associated with protection. We analyzed the IgG responses to individual Fim2 and Fim3 in sera remaining from a Swedish placebo-controlled efficacy trial that compared a whole-cell vaccine (diphtheria-tetanus-whole-cell pertussis vaccine [DTwP]), a two-component acellular pertussis vaccine (DTaP2), and DTaP5. One month following three doses of the Fim-containing vaccines (DTwP or DTaP5), anti-Fim2 geometric mean IgG concentrations were higher than those for anti-Fim3, with a greater anti-Fim2/anti-Fim3 IgG ratio elicited by DTaP5. We also determined the responses in vaccinated children following an episode of pertussis. Those who received DTaP5 showed a large rise in anti-Fim2 IgG, reflecting the predominant Fim2 serotype at the time. In contrast, those who received DTwP showed an equal rise in anti-Fim2 and anti-Fim3 IgG concentrations, indicating that DTwP may provide a more efficient priming effect for a Fim3 response following contact withB. pertussis. Anti-Fim2 and anti-Fim3 IgG concentrations were also determined in samples from two seroprevalence studies conducted in Sweden in 1997, when no pertussis vaccine was used and Fim2 isolates predominated, and in 2007, when either DTaP2 or DTaP3 without fimbriae was used and Fim3 isolates predominated. Very similar distributions of anti-Fim2 and anti-Fim3 IgG concentrations were obtained in 1997 and 2007, except that anti-Fim3 concentrations in 1997 were lower. This observation, together with the numbers of individuals with both anti-Fim2 and anti-Fim3 IgG concentrations, strongly suggests thatB. pertussisexpresses both Fim2 and Fim3 during infection.

Download Full-text